Sirnaomics is a biopharmaceutical company focused on the research, development, and commercialization of RNA interference (RNAi) therapeutics. The company leverages proprietary technologies to target a wide range of diseases, including cancer, liver diseases, and skin conditions. Sirnaomics is committed to transforming the landscape of therapeutic interventions through its innovative approach to RNAi.
The order this company entered each market — oldest to newest
Sirnaomics and Bloomage Biotech form strategic partnership
Sirnaomics and Bloomage Biotech form strategic partnership
Sign up to see the full signal feed
How Sirnaomics, Inc.'s international expansion compares to its competitors
Sirnaomics, Inc.YouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Sirnaomics, Inc.You | 0 | 0 | 0% | 0 | 32 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
Sirnaomics to present its GalAhead™ muRNA delivery platform at 2024 OPT Summit in Boston, showcasing dual-targeting RNAi therapy innovation for liver diseases.
Sirnaomics and Bloomage Biotech form strategic partnership with HK$138 million investment, focusing on RNAi therapies in medical aesthetics and regenerative medicine.
Sirnaomics and Bloomage Biotech form strategic partnership with HK$138 million investment, focusing on RNAi therapies in medical aesthetics and regenerative medicine.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Sirnaomics, Inc.'s business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
